New technology, developed by NeuroVision Imaging and Cedars-Sinai, is exploring the use of noninvasive eye imaging to detect Alzheimers disease, scanning the retina to identify protein deposits associated with the disorder.
The system is designed to look for neurotoxic beta-amyloid protein deposits, which are also found in the brain in Alzheimers patients. Normally, such deposits are found through the use of positron emission tomography, or through the analysis of cerebrospinal fluid, both of which are invasive and costly, researchers said.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.